New drug against glioblastoma is initially effective, but harmful on the long run


A new type of anti-cancer drug,  an EZH2 inhibitor, shows promising results against glioblastoma, but needs to be used with caution. The research group of Maarten van Lohuizen of the Netherlands Cancer Institute shows that prolonged Ezh2 inhibition results in tumor progression / tumors that are even more aggressive. Their study is published 'online first' in the journal Cell Reports on January 15.     

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.